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Increased oxidative stress has been implicated in both the onset and the progression of diabetes
mellitus and its complications. The development of easy to measure biomarkers of oxidative stress
would, therefore, help in determining in a prospective manner the impact of glycemic control on
oxidative stress and macrovascular disease in patients with diabetes. We report the development and
validation of a novel method to directly measure the urinary concentrations of the conjugated
metabolites of vitamin E (a-tocopherol) and investigate whether the oxidized metabolite a-tocopher-
onolactone (a-TL) could be used as a biomarker of oxidative stress in children with type 1 diabetes.
A novel method using liquid chromatography–tandem mass spectrometry was developed and used to
measure directly and rapidly the urinary concentrations of the glucuronidated and sulfated metabolites
of a-tocopherol in 32 young patients with type 1 diabetes and age-matched controls. The mean
concentrations of the glucuronidated and sulfated conjugates of a-TL were all highly signiﬁcantly
increased in the children with type 1 diabetes (po0.001). The results suggest that the measurement of
the urinary concentrations of a-TL conjugates may provide a useful biomarker of oxidative stress in
diabetes and possibly in other clinical conditions in which oxidative stress has been implicated.
& 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Over the past 50 years a number of metabolites of vitamin E
(a-tocopherol) have been described. These can be divided into two
groups. The ﬁrst includes a-tocopherylquinone, a-tocopheronic acid,
and a-tocopheronolactone (a-TL)1, all of which result from the
oxidation and opening of the chromanol ring of a-tocopherol [1,2].
The second group results from the successive shortening of the phytyl
side chain of a-tocopherol, initially by o-hydroxylation by a cyto-
chrome P450-dependent mechanism followed by b-oxidation [3,4],
and includes a-carboxymethylbutylhydroxychroman and a-carbox-
yethylhydroxychroman (a-CEHC) [5–7]. The principal reported urin-
ary metabolites of a-tocopherol are a-CEHC and a-TL, both of which
are excreted as their polar sulfate and glucuronide conjugates [5,8].
There is, however, doubt in the literature as to whether the a-TL2
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0.
ler).
-NC-ND license.observed in urine is a true metabolite or an artifact produced from
the oxidation of a-CEHC during the methodological workup [5,9].
Conﬁrmation of the authenticity of a-TL is important, as it could
potentially be used as an ex vivo biomarker of oxidative stress.
Published methods for the measurement of urinary vitamin E
metabolites typically involve deconjugation, extraction, and deri-
vatization steps, which are time consuming and risk the artifactual
formation of a-TL from a-CEHC [9]. We aimed to develop a new
and rapid method utilizing tandem mass spectrometry for the
direct assay of the intact conjugated vitamin E metabolites and to
investigate whether there was evidence for increased urinary
concentrations of a-TL conjugates under conditions where oxida-
tive stress may be implicated, such as diabetes mellitus [10,11].
Diabetes is a major risk factor for cardiovascular disease. In
patients with type 1 and type 2 diabetes, atherosclerosis occurs
early in life (childhood and adolescence), leading to increased
morbidity and mortality compared to the general population. In
addition those with suboptimal metabolic control have a higher
risk of developing macrovascular complications [12–14].
There seems to be a general agreement that the production of
oxygen-derived free radicals (ODFRs) is implicated in both the
onset and the progression of diabetes and its complications [10].
A number of mechanisms have been proposed to contribute to
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include an increased ﬂux through the polyol pathway, an
increased formation of advanced glycation end products, activa-
tion of protein kinase C, and an increased production of super-
oxide by the mitochondrial electron transport chain [10,15]. As a
result of an increased ODFR production, patients with diabetes are
likely to have a greater antioxidant requirement [16] and there is
some evidence suggesting that they have decreased concentra-
tions of antioxidants [17–19], including lower plasma a-toco-
pherol concentrations [20,21].
The development of biomarkers of oxidative stress that can be
easily measured would help determine prospectively the impact
of glycemic control on oxidative stress and macrovascular disease
in children and young people with type 1 diabetes. In this paper
we report the development and validation of a method to
measure urinary conjugated vitamin E metabolites, particularly
the glucuronidated and sulfated conjugates of a-TL, and its
application to children with type 1 diabetes. A summary of this
work has been previously reported in abstract form [22].Fig. 1. Parent ion scans ofMethods
Method development
The sulfated and glucuronidated conjugates of a-TL and a-
CEHC used in the method development and validation studies
were synthesized by Pope et al. [8,23].
The vitamin E metabolites were analyzed by mass spectro-
metry using a triple-quadrupole Micro Quattro instrument
(MicroMass, Waters, UK) ﬁtted with an electrospray ionization
source. The source and desolvation gas temperatures were held
constant at 150 and 350 1C, respectively, with ﬂow rates of 950
and 60 liters of nitrogen per hour. The optimum gas cell pressure
was set at 4  103 mbar.
Fig. 1 shows the tandem mass spectral analysis of vitamin E
metabolites obtained in scan mode over a mass range of 2–400
and 2–500m/z [MH] for the sulfate and glucuronide metabo-
lites, respectively. A mass was observed at m/z 357 [MH],
which corresponded to the theoretical mass of the sulfatedvitamin E metabolites.
G. Sharma et al. / Free Radical Biology and Medicine 55 (2013) 54–6256a-CEHC and a-TL (Figs. 1A and 1B). The mass observed at m/z
452.6 [MH] (Figs. 1C and 1D) corresponded to the theoretical
masses of a-CEHC and a-TL glucuronide. a-CEHC and a-TL have
the same molecular masses and are, therefore, isobaric.
Each compound was further characterized by fragmentation
studies using the mass spectrometer operating in the product ion
scan mode. The fragmentation analysis for the sulfate metabolites
was observed in a scan mode of 2–400m/z (Fig. 2A and B). The
fragmentation pattern of a-CEHC sulfate led to a ‘‘ﬁngerprint’’ ion
identiﬁed as a sulﬁte ion (SO3
) with an intensity of 79.7m/z.
Lesser intensity ions were observed at 276.9, 243.1, 233.1, and
163.1 m/z, which were attributed to the fragmentation of the
metabolite as shown in Fig. 2A. Fragmentation analysis of a-TL
sulfate (Fig. 2B) revealed the presence of a progeny and lesser
intensity ions similar to that of the a-CEHC sulfate, except no ion
at 243.1 m/z was observed.
The product ion analysis of the glucuronide metabolites was
conducted in scan mode between 2 and 500m/z. The highest
intensity ion was observed at 112.8m/z (Figs. 2C and 2D), which
was formed by the loss of H2O and CO2 from the glucuronide
moiety. Further fragmentation led to the formation of additional
ions at 233.1 and 276.6m/z. The fragmentations of the a-CEHC and
a-TL glucuronides were very similar and thus the two metabolites
could not be differentiated by mass spectral analysis alone.
The tandem mass spectral analyses of the internal standards
were obtained in a scan mode of 2–600 [MH]. Masses were
observed at 455.3 and 465.3m/z [MH], which were consistent
with the internal standards lithocholic acid sulfate and androsteroneFig. 2. Product ion scans ofglucuronide, respectively (not shown). The internal standards were
further characterized by fragmentation studies. This led to the
identiﬁcation of a daughter ion (HSO4) of lithocholic acid sulfate at
97m/z and a daughter ion of androsterone glucuronide at 112.8m/z.
Because of the isobaric nature of a-CEHC and a-TL and their
similar fragmentation patterns (with the exception of an ion at
243.1m/z in the case of a-CEHC sulfate), high performance liquid
chromatography was used together with tandem mass spectro-
metry to determine if it was possible to distinguish each vitamin E
metabolite by its chromatographic retention time in addition to
mass spectral analysis. Results from the use of a C8 column showed
it to be 10-fold more sensitive than an HsF5 column, and a C8
column was, therefore, used in the method development. The
chromatographic separations of the metabolites and internal
standards are shown in Fig. 3. Two peaks were observed for the
a-TL glucuronide, a major peak eluting at 8.37 min and a minor
one at 10.56 min. The minor peak was postulated to be an isomer
with the structure as illustrated on chromatogram in Fig. 3D and
had been observed previously by Pope [23]. These major and minor
peaks are referred to as a-TL glucuronide 1 and 2, respectively. The
elution times meant that all the vitamin E metabolites and internal
standards could be separated in a single run.
Final method
The sulfated and glucuronidated conjugates of a-TL and a-
CEHC were synthesized by Pope et al. [8,23]. The internal
standards (lithocholic acid sulfate and androsterone glucuronide)vitamin E metabolites.
Fig. 2. Continued.
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All the solvents were liquid chromatography–mass spectrometer
(LC–MS) grade or equivalent and were also obtained from Sigma–
Aldrich Co. Ltd. Neat urine (150 ml) was spun for 5 min at
1500 rpm and spiked with 10 ml of the internal standards
(100 mmol/L). Samples were vortexed and 15 ml was injected into
the LC–MS for analysis. The concentration of each vitamin E
metabolite in each patient urine sample was determined by
comparison of the ratio of the response of the metabolite to the
response of the internal standard and comparing it to a calibra-
tion curve created by spiking control urine with increasing
amounts of each standard. The control urine had endogenous
vitamin E metabolites removed by a cleanup procedure using C18
solid-phase extraction.
The urinary vitamin E metabolites were desalted and/or
separated before mass spectrometry using a Waters 2795XE
high-performance liquid chromatography unit ﬁtted with a 100
 2.1-mm (5 m) HyPURITY C8 column plus a guard column
containing the same stationary phase (Phenomenex UK). The LC
gradient started with 5% methanol:acetonitrile (MeOH:ACN, 2:1)
and 95% 4 mmol/L ammonium acetate (containing 0.01% formic
acid) for 4 min. The ammonium acetate was then replaced bywater (80%), which, together with MeOH:ACN (20%), was run for
1 min. This mixture was changed to water (55%) and MeOH:ACN
(45%) for 5.5 min. It was at this gradient that all the vitamin E
metabolites eluted between 7 and 10 min total run time. The
column was then washed with 100% MeOH:ACN for 5.5 min
before being reconditioned before the next injection with 5%
MeOH:ACN and 95% ammonium acetate (4 mmol/L containing
0.01% formic acid) for 4 min. The ﬂow rates varied from 0.25 to
0.55 ml/min. The total analysis time between each injection was
20 min. The mobile phase containing salts and other contami-
nants was diverted using the divert valve, away from the mass
spectrometer, during the ﬁrst 3 min. In this way at least 300
analyses could be performed before the ion source required
routine maintenance.
The vitamin E metabolites were detected using multiple-
reaction monitoring mode of the transitions at 356.9479.7 and
453.04112.8 m/z for the a-CEHC/TL sulfates and glucuronides,
respectively. Data were acquired over a period of 2–20 min, in
multiple-channel acquisition mode and with a dwell time for each
ion species of 50 ms. The cone voltages were 42 and 25 V for the
sulfates and glucuronides, respectively, and the collision voltages
were 26 and 36 eV, respectively.
Fig. 3. The LC–MS/MS analysis of vitamin E metabolites and internal standards.
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The urine samples were stored at either 20 or 80 1C before
analysis. To investigate any effects of storage on a-TL conjugate
concentrations, a batch of urine samples was stored at 20 1C
and analyzed at monthly intervals for 3 months. There were no
consistent or signiﬁcant increases in concentrations of the a-TL
conjugates or decreases in the a-CEHC conjugates.
To check the linearity of the method, increasing amounts of
each of the vitamin E metabolites (0, 0.5, 1, 1.5, 2.5, 5, and
10 nmol) were added to constant amounts of the internal stan-
dard and ethanol before analysis. The ratio of the areas for the
vitamin E metabolites over the corresponding internal standardwas calculated for each metabolite using MassLynx software. The
data obtained were analyzed by linear regression for which the
best ﬁt for the linear relationship was calculated using GraphPad
Prism. The correlation coefﬁcients (r2) were 40.99 for all the
metabolites. In subsequent studies it was found that the linearity
of the method ceased at amounts of approximately 15 nmol.
Recovery studies involved analysis before and after known
amounts of the metabolites (0.2, 0.5, and 2.5 nmol) were added to
150 ml of a laboratory control urine containing a constant amount of
internal standard. Triplicate injections at each concentration were
performed. The ratio of the areas for the vitamin E metabolites over
the corresponding internal standard was calculated for each meta-
bolite. From the amount of the metabolite present, the percentage
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the metabolites at the three concentrations varied from 90 to 100%.
To assess the reproducibility of the method, low, normal, and
high amounts of the conjugates of a-CEHC and a-TL (0.1, 0.5, and
2.5 nmol) were added to a laboratory control urine. The intra-
assay precision of the method was evaluated using 20 injections
of the three concentrations of the metabolites in the same run on
a single day. Interassay reproducibility was assessed by running a
single injection of the three concentrations on 20 separate
occasions over a period of 60 days. The ratio of the areas for the
vitamin E metabolites over the corresponding internal standard
was calculated for each metabolite. The intra-assay coefﬁcient of
variation for the metabolites ranged from 0.60 to 3.73% and the
interassay coefﬁcient of variation ranged from 1.18 to 4.32%.
The functional and biological limits of detection of the conjugated
metabolites were determined by sequentially diluting a known
amount of metabolite in ethanol (functional limit) and urine (biolo-
gical limit). A signal-to-noise ratio of 5:1 was taken to be the limit of
detection. The functional limit of detection for the metabolites varied
from 0.01 to 0.20 nmol (0.06 to 1.3 mmol/L) and the biological limit of
detection varied from 0.05 to 0.77 nmol (0.3 to 5.1 mmol/L).
The urinary concentrations of the vitamin E metabolites were
expressed per urinary creatinine concentrations, which were
measured by mass spectrometry using deuterated creatinine as
the internal standard (unpublished method).
Unless stated otherwise the results are expressed as means71
SEM. The signiﬁcance of differences between mean concentrations
was determined using the unpaired Student t test for analysis
between groups.
Clinical details
Thirty-two children and young people (16 male), with a mean age
at study of 12.9 years (range 7.8–18.4), with type 1 diabetes were
studied. Their mean age at diagnosis was 10.8 years and the average
duration of diabetes was 5 years. None of the subjects were receiving
any vitamin E supplements or pharmacological therapy at the time of
the study and were receiving only appropriate insulin therapy. A
urinary sample for measurement of vitamin E metabolites was
obtained at a routine clinic visit and glycosylated hemoglobin
(HbA1c) was measured as part of the standard clinic appointment
using the Diabetes Control and Complications Trial-aligned Bayer
2000þ system (Siemens Healthcare Diagnostics, Deerﬁeld, IL, USA).
The same 32 age- and sex-matched healthy control subjects
were investigated throughout the study and were drawn from the
University College London Fetal Growth Study. This study consists
of 1650 consecutive mothers who delivered a singleton, Cauca-
sian baby free of pregnancy complications and whose offspring’s
growth has been followed for the past 10 years. As part of the
follow-up of these children urine samples were obtained con-
temporaneous with the type 1 diabetes study. There was no
signiﬁcant difference between the body mass indexes (BMIs) of
the diabetic subjects and controls. The BMI expressed as a
standard deviation score was 0.0 (SD 0.9) for the diabetic subjects
and 0.1 (SD 0.8) for the controls.
Ethical approval was obtained from the Ethics Committees of
University College London Hospital/University College London and
Great Ormond Street Hospital for Sick Children/Institute of Child
Health. Written informed consent was obtained from the parents
and from the children and young people where appropriate.Results
Concentrations of urinary vitamin E metabolites were quantiﬁed
in 32 patients with type 1 diabetes mellitus and 32 age-matchedcontrols. Fig. 4A–E show the range and mean concentration per
creatinine for each of the metabolites with levels of signiﬁcance
between the subjects with diabetes and the controls. The results are
summarized in Table 1. The mean concentrations of the a-TL
conjugates are all highly signiﬁcantly increased in the patients with
diabetes (po0.001). The concentrations of the a-CEHC conjugates
were also signiﬁcantly increased (po0.05) in the patients with
diabetes. The cohort with diabetes excreted approximately eight-
fold greater concentrations of the vitamin E metabolites than the
control subjects. This was also true for the urinary concentrations of
both total glucuronide (10) and sulfate (3.5) conjugates. In
addition the concentrations of the glucuronide metabolites were
greater than those of the sulfates in both cohorts. The concentra-
tions of the glucuronidated and sulfated a-CEHC were similar
within each cohort. There were, however, greater concentrations
of both a-CEHC glucuronide and sulfate in the group with diabetes
compared to controls. The control subjects excreted similar
amounts of a-CEHC glucuronide and a-TL glucuronide.
The concentrations of the urinary vitamin E conjugates were
also compared after dividing the patients with diabetes into two
groups according to their glycosylated hemoglobin concentration:
6–7.5% (42–58 mmol/mol) HbA1c (i.e., well controlled; n¼8) and
47.5% (458 mmol/mol) HbA1c (poorly controlled; n¼24). The
results are summarized in Table 2. With the exception of a-CEHC
sulfate, the urinary concentrations of the a-tocopherol conjugates
were similar in the two groups of patients with type 1 diabetes.
The a-TL conjugates in both groups with diabetes remained highly
signiﬁcantly increased compared to the control group, whereas,
with the exception of a-CEHC sulfate in the well controlled
diabetic group, the concentrations of the a-CEHC conjugates were
no longer signiﬁcantly different from the controls.Discussion
The method described in this paper using LC–MS/MS for the
direct measurement of the conjugated metabolites of vitamin E is
novel as previous methods used gas chromatography–mass spec-
trometry (GC–MS) and were able to analyze only the free
unconjugated metabolites. In addition the method has distinct
advantages over previous methods. First it is direct and requires
only minimal sample preparation, i.e., a centrifugation step to
remove particulate matter. This is in contrast to the method of
Pope et al. [9] and Lodge et al. [24] which required long
deconjugation, extraction, and derivatization procedures before
analysis by GC–MS. In addition because of the intact conjugate
and short preparation time there is little risk of artifact formation.
In contrast artifactual formation of a-TL from free a-CEHC can
occur during the assay of the free metabolites [5,9]. It would have
been ideal to use deuterated conjugated vitamin E metabolites as
internal standards for this study but this was not possible. Thus
type II internal standards (androsterone glucuronide and litho-
cholic acid sulfate) were used.
We have established and validated a simple, fast, and repro-
ducible assay for directly quantitating the urinary conjugated
vitamin E metabolites and shown unequivocally for the ﬁrst time
that conjugates of a-TL were real metabolites and not artifacts of
the methodological procedure. Thus it was possible to investigate
whether conjugated a-TL could be used as a biomarker of
oxidative stress. The hypothesis put forward in this study was
that the urinary concentrations of a-TL (sulfate and glucuronide)
would be greater in patients with diabetes compared to age-
matched controls, with less change in the concentrations of
conjugated a-CEHC.
The total urinary concentrations of all the metabolites (sulfate
and glucuronide) were found to be greater, by a factor of
α-TL gluc 1 α-TL gluc 2
α-TL sulphate
α-CEHC gluc α-CEHC sulphate
Fig. 4. Urinary concentrations of the conjugated metabolites of a-tocopherol (nmol/mmol creatinine).
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age-matched controls, with the total concentration of a-TL
(glucuronide and sulfate) being approximately 15 times greater
and the total a-CEHC (glucuronide and sulfate) being 2 times
greater than in the control subjects. The ratio of a-TL:a-CEHC was
approximately 7 in the cohort with diabetes compared to 0.9 inthe controls. When the individual conjugated metabolites were
compared in the two groups, the mean concentrations of the
conjugated a-TL metabolites in the patients with diabetes were
all highly signiﬁcantly increased (po0.001) compared to the
controls, whereas the a-CEHC conjugates were not increased to
the same degree of signiﬁcance (po0.05). This suggests that
Table 2
Signiﬁcance of difference between well and poorly controlled groups of diabetic
subjects and controls and also between the two diabetic groups.
6–7.5 HbA1c%
(42–58 mmol/mol)a,
n¼8 (p compared to
controls)
47.5 HbA1c%
(458 mmol/mol)a,
n¼24 (p compared to
controls)
Interdiabetic
pb
a-TL-glucuronide 1c 10347351 (o0.001) 11197356 (o0.002) NS
a-TL-glucuronide 2c 305786 (o0.002) 443791 (0.001) NS
a-TL-sulfate 110743 (0.0002) 68712 (o0.0001) NS
a-CEHC-
glucuronide
131740 (NS) 124718 (NS) NS
a-CEHC-sulfate 174760 (o0.005) 90713 (NS) o0.05
Concentrations are given in nmol/mmol creatinine; mean7SEM. NS, not
signiﬁcant.
a HbA1c mmol/mol¼(HbA1c%  2.15)  10.929.
b The signiﬁcance of differences between mean concentrations was deter-
mined using the unpaired Student t test for analysis between groups.
c Two peaks were observed for the a-TL glucuronide, a major peak eluting at
8.37 min and a minor one at 10.56 these major and minor peaks are referred to as
a-TL glucuronide 1 and 2, respectively.
Table 1
Urinary concentrations of vitamin E metabolites.
Patients with type
1 diabetes (D),
n¼32
Controls (C),
n¼32
pa Ratio
(D:C)
a-TL glucuronide 1b 10987279 76713 o0.001 14.5
a-TL glucuronide 2b 441773 3479 o0.001 13.0
a-CEHC glucuronide 126716 73719 o0.05 1.7
Total glucuronide 1786 183 9.8
a-TL sulfate 98724 1072 o0.001 9.8
a-CEHC sulfate 138733 57712 o0.05 2.4
Total sulfate 236 67 3.5
Total a-TL 1758 120 14.7
Total a-CEHC 264 130 2.0
Total metabolites 2022 250 8.1
Concentrations are given in nmol/mmol creatinine; mean7SEM.
a The signiﬁcance of differences between mean concentrations was deter-
mined using the unpaired Student t test for analysis between groups.
b Two peaks were observed for the a-TL glucuronide, a major peak eluting at
8.37 min and a minor one at 10.56 min; these major and minor peaks are referred
to as a-TL glucuronide 1 and 2, respectively.
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urinary excretion of the conjugated metabolites. Although plasma
concentrations of a-tocopherol were not compared in the two
groups, these results suggest an increased metabolism of vitamin
E in patients with diabetes compared to controls, with oxidation
of a-tocopherol being more prominent than chain shortening.
This is compatible with an increase in oxidative stress in diabetes
and suggests that conjugated a-TL may be a useful biomarker.
Essentially similar results were obtained when the patients
with diabetes were divided on the basis of their glycosylated
hemoglobin concentrations into those who were poorly and those
who were well controlled. There was also no signiﬁcant correla-
tion between the concentrations of the a-TL conjugates and the
HbA1c levels in all the diabetic patients. There was, therefore, no
evidence from this study that the poorly controlled patients had
an increased oxidative stress compared to the subjects with better
control. To examine this further it will be necessary to follow a
larger cohort of patients with diabetes longitudinally and com-
pare urinary concentrations of conjugated a-TL with other well-
recognized measures of diabetes control, such as HbA1c and
urinary albumin concentrations. The results of this study
strengthen the hypothesis put forward by Liebler et al. [25] andSchonfeld et al. [26] that a-TL could be an indicator/biomarker of
oxidative stress but the nature of the relationship between
clinical severity of diabetes and oxidative stress status requires
further investigation.
We have no ready explanation as to why the children with
type 1 diabetes excreted increased urinary concentrations of the
conjugated vitamin E metabolites compared to the controls. They
were not receiving any vitamin E supplementation or pharmaco-
logical therapy at the time of the study. We can only speculate
that an increase in metabolism of vitamin E and particularly
oxidation occurs as a result of the underlying condition. It is,
however, of interest that a link between vitamin E and glucose
metabolism has been reported [27]. In particular it was found that
when mice deﬁcient for the a-tocopherol transport protein (a-TTP)
were supplemented with a-tocopherol there was an increase in
their glucose tolerance.
The liver, and in particular the hepatic a-TTP, has a key role in
discriminating between the various forms of vitamin E by loading
a-tocopherol onto very low density lipoprotein (VLDL) and
thereby maintaining plasma and tissue a-tocopherol concentra-
tions (see Traber et al. [28]). Presumably those forms of vitamin E
including metabolites of a-tocopherol that are not loaded onto
VLDL are preferentially excreted.
The concentrations of the glucuronide metabolites were greater
than the sulfates in both the cohorts, with the glucuronide:sulfate
ratio being approximately 8 in patients with diabetes and 3 in the
controls. This was expected as humans have a greater capacity for
glucuronidation than sulfation [29] because of a high activity of the
hepatic enzyme UDP-glucuronyltransferase [30]. Similar observa-
tions of preferential glucuronidation of the vitamin E metabolites
were made by Pope when he conducted LC–MS/MS analysis on
normal human urine [23].
An increase in the concentrations of other biomarkers of
oxidative stress in patients with diabetes has been previously
observed by a number of researchers. Thus Dandona et al. [31]
observed an approximately fourfold greater concentration of
8-hydroxy-20-deoxyguanosine in mononuclear cells of patients
with diabetes compared to corresponding controls. This differ-
ence was statistically signiﬁcant and demonstrated for the ﬁrst
time greater oxidative damage to DNA in such individuals. Davi
et al. [32] were the ﬁrst group to demonstrate that the increased
8-epi-PGF2a observed in both type 1 and type 2 diabetes patients
could be normalized by vitamin E supplementation. Leonhardt
et al. [33] had previously reported elevated levels of oxidized LDL
and decreased concentrations of RRR-a-tocopherol in the plasma
of patients with diabetes compared to healthy controls, making a
case for investigating the role of vitamin E metabolites in
diabetes. Others have reported reduced concentrations of anti-
oxidants including vitamin E in diabetes (see [10]), and the role of
vitamin E and oxidative stress in diabetes has recently been
reviewed [34].
To fully validate the use of urinary conjugates of a-TL as a
potential biomarker of oxidative stress, it will be necessary to
synthesize the deuterated conjugates of a-TL and a-CEHC to use
them as internal standards for the assay in place of the current
type II internal standards (androsterone glucuronide and litho-
cholic acid sulfate) and to carry out the following additional
studies. First, prospective longitudinal studies of urinary vitamin
E metabolites will be required in subjects with diabetes, compar-
ing the excretion of a-TL conjugates with other parameters of
diabetic control such as plasma HbA1c and urinary albumin
concentrations. Second, urinary concentrations of a-TL conjugates
will need to be compared with other biomarkers of oxidative
stress such as urinary isoprostanes. Finally, it will be important to
investigate the urinary concentrations of a-TL conjugates in other
conditions in which oxidative stress has been implicated.
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